Ki67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients

Haroon, Saroona; Hashmi, Atif Ali; Khurshid, Amna; Kanpurwala, Muhammad Adnan; Mujtuba, Shafaq; Malik, Babar; Faridi, Naveen

doi:10.7314/apjcp.2013.14.7.4353

“…However, Ki67 expression levels were previously reported in several small-sample BC studies (13,21,22). Haroon et al (13) identified that ~39.8% (78/194) of the BC patients included in the study exhibited a low Ki67 expression (cut-off, 15%), while Fasching et al observed the same in ~29.3% (162/552; cut-off, 13%) of the included patients (21). Furthermore, ~36.2% (471/1,302) of invasive ductal BC patients and 59.7% (237/397) of invasive lobular BC patients demonstrated a low Ki67 expression (cut-off, 14%) in a study by Heusinger et al (22).…”

Section: Discussionmentioning

confidence: 90%

“…Until recently, limited information was available regarding the expression of Ki67 among Chinese females with BC. Furthermore, previous studies on the association between Ki67 and other clinicopathological parameters have only included small sample sizes (13)(14)(15); therefore, this association remains controversial. The aim of the present study was to investigate the distribution of Ki67 expression and its association with other clinicopathological parameters.…”

Section: Introductionmentioning

confidence: 99%

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study

Sun

¹

,

Chen

²

,

Wen

³

et al. 2015

View full text Add to dashboard Cite

Abstract. Ki67 has potential prognostic and predictive values for breast cancer patients, and has become an important biomarker in routine clinical practice. The aims of the present study were to investigate the distribution of Ki67 expression and its correlation with other clinicopathological parameters in central China. In total, 1,259 patients with newly-diagnosed invasive breast cancer were included in the present study. The clinical information was obtained from the electronic medical records. The expression levels of Ki67, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were detected by immunohistochemical analysis. The associations between Ki67 scores and other prognostic factors were evaluated as continuous and categorical variables. The mean value of the Ki67 scores of all patients was 31%. In total, ~36% (456/1,259) of the patients demonstrated a low expression of Ki67. A statistically significant correlation was identified between the mean Ki67 scores and the lymph node status, tumor grade, ER, PR and HER2 status, and clinical stage or molecular subtypes (all P<0.001). When Ki67 was categorized into high (>14%) and low (≤14%) level groups, the χ 2 test was used to verify these results. The Ki67 scores demonstrated no statistically significant differences between the HER2-positive (non-luminal) and three negative subtypes, with the exception of patients with a tumor size of >2 cm (P=0.02). In conclusion, the results revealed the presence of significant correlations between Ki67 and other clinicopathological parameters.

show abstract

“…It is mainly located in the cell nucleus, plays an important role of maintaining the structure of the DNA stable in mitosis. It has no expression in the G0 phase of the cell cycle (Haroon et al, 2013), begins to appear in the G1 phase, increases gradually in the S phase and G2 phase (Tadbir et al, 2012), reaches the peak in the M phase, and declines rapidly in the late stage of cell division. Ki67 gene is considered as a kind of proto-oncogene at present, which locates on chromosome 10q25 and its molecular weight is 345000 (Ye et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance

Zhang¹,

Jiang²,

Lü³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and to analyze its clinical significance. Materials and Methods: Ki67 protein expression was evaluated in the tissues of 108 human PTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry. Results: The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimens were 1.45±1.83% and 0.46±0.46%.The positive expression rates were 46.3% and 14%. There were significant differences between these two groups (p<0.01). There was no significant variation of the expression intensity and positive expression rates of Ki67 in PTMC with gender, age, position of the tumor and the level of TSH pre-operation (p>0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymph node metastasis (p<0.05 or p<0.01). Conclusions: The expression of Ki67 in PTMC was related to tumor size, invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judging clinical progress and estimating prognosis.

show abstract

“…A study that included a cohort of Pakistani patients revealed a significant association between Ki67 expression and tumor grade, PR, HER2 and lymph node status. However, no correlation was identified between the ER status and tumor size (13). The earliest study conducted in the United Kingdom, demonstrated a significant association between the Ki67 index and the histological grade, size and type of the tumors (14).…”

Section: Discussionmentioning

confidence: 99%

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population‑based study

Sun

¹

,

Chen

²

,

Wen

³

et al. 2015

View full text Add to dashboard Cite

Abstract. Ki67 has potential prognostic and predictive values for breast cancer patients, and has become an important biomarker in routine clinical practice. The aims of the present study were to investigate the distribution of Ki67 expression and its correlation with other clinicopathological parameters in central China. In total, 1,259 patients with newly-diagnosed invasive breast cancer were included in the present study. The clinical information was obtained from the electronic medical records. The expression levels of Ki67, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were detected by immunohistochemical analysis. The associations between Ki67 scores and other prognostic factors were evaluated as continuous and categorical variables. The mean value of the Ki67 scores of all patients was 31%. In total, ~36% (456/1,259) of the patients demonstrated a low expression of Ki67. A statistically significant correlation was identified between the mean Ki67 scores and the lymph node status, tumor grade, ER, PR and HER2 status, and clinical stage or molecular subtypes (all P<0.001). When Ki67 was categorized into high (>14%) and low (≤14%) level groups, the χ 2 test was used to verify these results. The Ki67 scores demonstrated no statistically significant differences between the HER2-positive (non-luminal) and three negative subtypes, with the exception of patients with a tumor size of >2 cm (P=0.02). In conclusion, the results revealed the presence of significant correlations between Ki67 and other clinicopathological parameters.

show abstract

Ki67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients

Cited by 61 publications

References 42 publications

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study

Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population‑based study

Contact Info

Product

Resources

About